Halozyme Therapeutics | HALO - Bienes





Bienes Cambio Fecha
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amarin USD 645.76M 25.01M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Baxter International USD 19.85B 209M 2026-03
Cara Therapeutics USD 32.07M 6.95M 2025-12
Cytokinetics USD 1.27B 151.06M 2026-03
DBV Technologies USD 223.2M 43.2M 2026-06
Eli Lilly USD 116.58B 4.1B 2026-03
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Intrexon USD 73.16M 77.88M 2024-06
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
MannKind USD 744.4M 47.78M 2026-03
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Pfizer USD 207.62B 542M 2026-03
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
United Therapeutics USD 6.71B 1.17B 2026-03
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12